Work

Faculty Opinions recommendation of Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

Year: 2013

Type: peer-review

Source: Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

DOI: 10.3410/f.717969624.793480214

Authors: Keith Flaherty, Ryan Sullivan

Institutions: Massachusetts General Hospital, Beth Israel Deaconess Medical Center

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4234675763

Cites:

Cited by:

Related to: 10